ANZ 1601/BIG 16-02: EXPERT

BCT Study Chair:

Boon Chua

EXPERT aims to improve personalised use of radiation therapy in early breast cancer patients by using a genomic test to identify women who can safely avoid this treatment after surgery and the possible side effects.


The current standard of care for patients with early breast cancer is radiation therapy (RT) after breast conserving surgery, to improve local control and survival. However, breast cancer is a complex disease, and the absolute benefit of RT in individual patients varies substantially. This approach potentially may lead to overtreatment for a substantial proportion of patients and unnecessary treatment toxicity, financial costs and logistical challenges for patients. However, randomised trials have not consistently identified patients who may safely avoid RT using conventional clinical-pathologic characteristics.

EXPERT is an investigator-initiated trial which presents a unique opportunity to improve personalised use of radiation therapy in patients with early breast cancer according to their individual risks of local recurrence.

The primary aim of the trial is to see whether a genomic test of breast cancer tissue can be used to identify women who can safely avoid radiation therapy after breast cancer surgery. The need for radiation therapy after breast cancer surgery depends on the risk of the cancer reoccurring. If the risk is very small, there may be no need for radiation therapy. If a doctor could identify women who have a very small risk of the cancer coming back, these women may not need radiation therapy and could avoid its side effects.

Patients who have completed breast cancer surgery and consent to participate in EXPERT will have a piece of tumour tissue (from surgery) submitted for Prosigna Breast Cancer Gene Signature Assay (PAM50) testing. The PAM50 Assay is a validated assay which examines the type and level of gene expression within the tumour. The pattern of gene expression is used determine the breast cancer type and to predict the likelihood of the cancer returning, or the risk of recurrence which is scored between 1 and 100.

The EXPERT study is suitable for patients with a type of cancer called “luminal A breast cancer” that has a risk score of 60 or less. Those who are not eligible (based on cancer subtype and/or score) will continue with treatment off study in consultation with their clinician and will take no further part in the study.

A total of 1,170 eligible women (globally) will be recruited to this trial worldwide, including at 35 institutions in Australia and New Zealand.

Breast Cancer Trials leads the study in Australia and New Zealand with the Taiwan Breast Cancer Consortium (TBCC) leading the study in Taiwan. The Breast International Group (BIG) consortium leads the study in Italy, Spain, Switzerland, Argentina and Chile through the following international study groups:

  • Groupo Oncologico Cooperativo Chileno de Investigacin (GOCCHI)
  • Grupo Argentino de Investigacion Clinica en Oncologia (GAICO)
  • Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
  • International Breast Cancer Study Group (IBCSG)
  • SOLTI-Innovative Breast Cancer Research (SOLTI)


Professor Boon Chua is the BCT Study Chair of the EXPERT clinical trial.


Early Breast Cancer